37588789|t|Circulating oxylipin and bile acid profiles of dexmedetomidine, propofol, sevoflurane, and S-ketamine: a randomised controlled trial using tandem mass spectrometry.
37588789|a|Background: This exploratory study aimed to investigate whether dexmedetomidine, propofol, sevoflurane, and S-ketamine affect oxylipins and bile acids, which are functionally diverse molecules with possible connections to cellular bioenergetics, immune modulation, and organ protection. Methods: In this randomised, open-label, controlled, parallel group, Phase IV clinical drug trial, healthy male subjects (n=160) received equipotent doses (EC50 for verbal command) of dexmedetomidine (1.5 ng ml-1; n=40), propofol (1.7 mug ml-1; n=40), sevoflurane (0.9% end-tidal; n=40), S-ketamine (0.75 mug ml-1; n=20), or placebo (n=20). Blood samples for tandem mass spectrometry were obtained at baseline, after study drug administration at 60 and 130 min from baseline; 40 metabolites were analysed. Results: Statistically significant changes vs placebo were observed in 62.5%, 12.5%, 5.0%, and 2.5% of analytes in dexmedetomidine, propofol, sevoflurane, and S-ketamine groups, respectively. Data are presented as standard deviation score, 95% confidence interval, and P-value. Dexmedetomidine induced wide-ranging decreases in oxylipins and bile acids. Amongst others, 9,10-dihydroxyoctadecenoic acid (DiHOME) -1.19 (-1.6; -0.78), P<0.001 and 12,13-DiHOME -1.22 (-1.66; -0.77), P<0.001 were affected. Propofol elevated 9,10-DiHOME 2.29 (1.62; 2.96), P<0.001 and 12,13-DiHOME 2.13 (1.42; 2.84), P<0.001. Analytes were mostly unaffected by S-ketamine. Sevoflurane decreased tauroursodeoxycholic acid (TUDCA) -2.7 (-3.84; -1.55), P=0.015. Conclusions: Dexmedetomidine-induced oxylipin alterations may be connected to pathways associated with organ protection. In contrast to dexmedetomidine, propofol emulsion elevated DiHOMEs, oxylipins associated with acute respiratory distress syndrome, and mitochondrial dysfunction in high concentrations. Further research is needed to establish the behaviour of DIHOMEs during prolonged propofol/dexmedetomidine infusions and to verify the sevoflurane-induced reduction in TUDCA, a suggested neuroprotective agent. Clinical trial registration: NCT02624401.
37588789	25	34	bile acid	Chemical	MESH:D001647
37588789	47	62	dexmedetomidine	Chemical	MESH:D020927
37588789	64	72	propofol	Chemical	MESH:D015742
37588789	74	85	sevoflurane	Chemical	MESH:D000077149
37588789	91	101	S-ketamine	Chemical	MESH:C000629870
37588789	229	244	dexmedetomidine	Chemical	MESH:D020927
37588789	246	254	propofol	Chemical	MESH:D015742
37588789	256	267	sevoflurane	Chemical	MESH:D000077149
37588789	273	283	S-ketamine	Chemical	MESH:C000629870
37588789	291	300	oxylipins	Chemical	MESH:D054883
37588789	305	315	bile acids	Chemical	MESH:D001647
37588789	636	651	dexmedetomidine	Chemical	MESH:D020927
37588789	673	681	propofol	Chemical	MESH:D015742
37588789	704	715	sevoflurane	Chemical	MESH:D000077149
37588789	740	750	S-ketamine	Chemical	MESH:C000629870
37588789	1073	1088	dexmedetomidine	Chemical	MESH:D020927
37588789	1090	1098	propofol	Chemical	MESH:D015742
37588789	1100	1111	sevoflurane	Chemical	MESH:D000077149
37588789	1117	1127	S-ketamine	Chemical	MESH:C000629870
37588789	1236	1251	Dexmedetomidine	Chemical	MESH:D020927
37588789	1286	1295	oxylipins	Chemical	MESH:D054883
37588789	1300	1310	bile acids	Chemical	MESH:D001647
37588789	1328	1359	9,10-dihydroxyoctadecenoic acid	Chemical	-
37588789	1361	1367	DiHOME	Chemical	-
37588789	1402	1420	12,13-DiHOME -1.22	Chemical	-
37588789	1460	1468	Propofol	Chemical	MESH:D015742
37588789	1478	1489	9,10-DiHOME	Chemical	-
37588789	1521	1533	12,13-DiHOME	Chemical	-
37588789	1597	1607	S-ketamine	Chemical	MESH:C000629870
37588789	1609	1620	Sevoflurane	Chemical	MESH:D000077149
37588789	1631	1656	tauroursodeoxycholic acid	Chemical	MESH:C031655
37588789	1658	1663	TUDCA	Chemical	MESH:C031655
37588789	1708	1723	Dexmedetomidine	Chemical	MESH:D020927
37588789	1831	1846	dexmedetomidine	Chemical	MESH:D020927
37588789	1848	1856	propofol	Chemical	MESH:D015742
37588789	1875	1882	DiHOMEs	Chemical	-
37588789	1884	1893	oxylipins	Chemical	MESH:D054883
37588789	1910	1945	acute respiratory distress syndrome	Disease	MESH:D012128
37588789	1951	1976	mitochondrial dysfunction	Disease	MESH:D028361
37588789	2058	2065	DIHOMEs	Chemical	-
37588789	2083	2091	propofol	Chemical	MESH:D015742
37588789	2092	2107	dexmedetomidine	Chemical	MESH:D020927
37588789	2136	2147	sevoflurane	Chemical	MESH:D000077149
37588789	2169	2174	TUDCA	Chemical	MESH:C031655
37588789	Comparison	MESH:C000629870	MESH:D020927
37588789	Comparison	MESH:D000077149	MESH:D020927
37588789	Association	MESH:D001647	MESH:D015742
37588789	Comparison	MESH:D000077149	MESH:D015742
37588789	Negative_Correlation	MESH:D001647	MESH:D020927
37588789	Positive_Correlation	MESH:D020927	MESH:D012128
37588789	Comparison	MESH:C000629870	MESH:D015742
37588789	Positive_Correlation	MESH:D020927	MESH:D028361
37588789	Negative_Correlation	MESH:C031655	MESH:D000077149
37588789	Association	MESH:D000077149	MESH:D012128
37588789	Comparison	MESH:D015742	MESH:D020927
37588789	Negative_Correlation	MESH:D020927	MESH:D054883

